

Genetics of Type 2 Diabetes – Pathogenesis, Function, and Treatment

Special Edition of *The Review of Diabetic Studies*, Vol. 12, No. 3-4, 2015/2016

Table of Contents

Chapter I. Pathogenesis	231
I.1 Genetics of Type 2 Diabetes: It Matters From Which Parent We Inherit the Risk by <i>Valeriya Lyssenko, Leif Groop & Rashmi B. Prasad</i>	233
1. Introduction.....	233
2. Heritability of T2D and related metabolic risk factors.....	234
3. Genetic risk factors for type 2 diabetes.....	234
4. Genetic risk factors for insulin secretion.....	235
5. Genes for type 2 diabetes and parent-of-origin effects.....	236
5.1 Growth factor receptor-bound protein 10 (GRB10).....	236
5.2 Potassium channel, voltage-gated, KQT-like subfamily, member 1 (KCNQ1).....	236
5.3 Kruppel-like factor 14 (KLF14).....	237
5.4 PEG3, H19, and IGF2.....	237
5.5 MOB2 and others.....	238
6. Why parent-of-origin effects should not be overlooked.....	238
4. Conclusions.....	238
I.2 Novel Genetic Actors of Diabetes-Associated Microvascular Complications: Retinopathy, Kidney Disease and Neuropathy by <i>Samaneh Davoudi & Lucia Sobrin</i>	243
1. Introduction.....	243
2. Diabetic retinopathy.....	244
2.1 Heritability and linkage studies.....	244
2.2 Candidate gene association studies.....	245
2.3 Genome-wide association studies.....	247
3. Diabetic kidney disease.....	248
3.1 Heritability and linkage studies.....	248
3.2 Candidate gene association studies.....	249
3.3 Genome wide association studies.....	251
3.4 Exome sequencing.....	253
4. Diabetic neuropathy.....	253
4.1 Linkage studies.....	253
4.2 Candidate gene association studies.....	253
4.3 Genome wide association studies.....	254
5. Epigenetic factors.....	254
6. Conclusions.....	255
I.3 Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes by <i>Johanna K. DiStefano</i>	260
1. Introduction.....	260
2. The role of miRNAs in T2D pathogenesis.....	263
2.1 miRNAs involved in the regulation of pancreatic β -cell function.....	263
2.2 miRNA profiling of pancreatic islets and β -cells.....	266
2.3 miRNA dysregulation in insulin-sensitive peripheral tissues.....	268
2.4 Genetic variation, miRNAs, and susceptibility to T2D.....	270
3. lncRNAs and T2D pathogenesis.....	270
6. Summary.....	271
I.4 Genetic Determination of Serum Levels of Diabetes-Associated Adipokines by <i>Dorit Schleinitz</i>	277
1. Introduction.....	277
2. Genetic variants associated with serum adipokine concentration.....	278
2.1 Adiponectin (ADIPOQ).....	278
2.2 Chemerin (RARRES2).....	279
2.3 Leptin (LEP).....	282

2.4 Progranulin (PGRN).....	283
2.5 Resistin (RETN).....	283
2.6 Retinol binding protein 4 (RBP4).....	284
2.7 Vaspin (SERPINA12).....	285
2.8 Further adipokines.....	285
3. Adipokine receptors.....	286
3.1 Adiponectin receptor 1 and 2 (ADIPOR1, ADIPOR2), cadherin 13 (CDH13).....	286
3.2 Chemerin chemokine-like receptor 1 (CMKLR1).....	287
3.3 Leptin receptor (LEPR).....	287
3.4 Sortilin 1 (SORT1).....	288
3.5 CAP, adenylate cyclase-associated protein 1 (CAP1).....	288
3.6 Stimulated by retinoic acid 6 (STRA6).....	288
3.7 Kallikrein 7 (hK7), heat shock protein family A (Hsp70) member 5 (GRP78).....	289
3.8 Complement component 3a receptor 1 (C3AR1), apelin receptor (APLNR) & omentin (ITLN1).....	289
4. Epigenetics.....	289
5. Concluding remarks.....	290

I.5 Complex Genetics of Type 2 Diabetes and Effect Size: What have We Learned from Isolated Populations? by *Anup K. Nair & Leslie J. Baier*..... 299

1. Type 2 diabetes - an introduction.....	299
2. Type 2 diabetes is heritable.....	299
2.1 Familial aggregation.....	299
2.2 Twin studies.....	300
2.3 Heritability of related traits.....	300
2.4 Different prevalence in different ethnic groups.....	300
3. Delineating the heritability of T2D.....	301
3.1 Physiologic candidate gene studies.....	301
3.2 Family-based linkage studies.....	301
3.3 Genome-wide association studies (GWASs).....	301
3.4 GWAS imputation and meta-analysis.....	302
3.5 GWAS imputation and meta-analysis in diverse ethnic groups.....	302
4. What have we learned about the heritability of T2D?.....	302
4.1 Many variants with modest effects.....	303
4.2 Association does not imply causality.....	304
4.3 Most of the heritability remains unexplained.....	304
4.4 Limited overlap between variants influencing glucose- and insulin-related traits and T2D.....	305
5. Using isolated populations to study complex diseases.....	305
5.1 Population isolates.....	306
5.2 Genetic consequences of isolation.....	306
6. Advantages of studying population isolates for complex diseases.....	306
6.1 Less genetic variability.....	306
6.2 Enrichment of rare variants.....	306
6.3 More uniform environment and lifestyle.....	307
6.4 Enrichment of disease prevalence.....	307
6.5 More uniform clinical measures.....	307
6.6 Better access to patients and their families.....	307
7. Population Isolates studied for T2D.....	307
7.1 The Pima Indians of Arizona.....	307
7.2 The Amish of the Lancaster County.....	308
7.3 Isolated populations from Finland, Iceland, and Greenland.....	309
7.4 The Natives of Kosrae.....	309
7.5 Population from the Adriatic coast of Croatia.....	309
7.6 Oji-Cree population from Canada.....	310
8. Results of studies of T2D in isolated populations.....	310
8.1 HNF1A G319S is a major determinant of T2D in Canadian Oji-Cree population.....	310
8.2 A null mutation in hormone-sensitive lipase (LIPE) increases risk for T2D in the Old Order Amish.....	311
8.3 A loss-of-function mutation in ABCC8 increases the risk for T2D in Pima Indians.....	311
8.4 DNER, which functions in the NOTCH signaling pathway, is a T2D gene in Pima Indians.....	311
8.5 Variation in GCK can contribute to type 2 diabetes by affecting non-insulin secretory mechanisms in Pima Indians.....	311
8.6 A null mutation in TBC1D4 increases the risk for T2D in the Greenlandic population.....	312
9. Comparison of T2D loci in isolated vs. outbred populations.....	312
9.1 Analysis of established T2D variants in isolated population.....	312
9.2 Allele frequency differences at established T2D loci do not explain the higher prevalence in Pima Indians (Figures 2 and 3).....	313

10. Exploring an additional heritable mechanism: parent of origin.....	313
11. Going forward.....	314
I.6 Diabetes in Population Isolates: Lessons from Greenland by <i>Niels Grarup, Ida Moltke, Anders Albrechtsen & Torben Hansen</i>	320
1. Prevalence of type 2 diabetes.....	320
2. Genetic characteristics of the Greenlandic population.....	321
3. GWAS in population isolates.....	322
4. The p.Arg684Ter nonsense variant TBC1D4 identified in Greenland imposes high effects on glycaemic traits.....	323
5. The TBC1D4 p.Arg684Ter variant defines a subtype of type 2 diabetes characterized by isolated peripheral insulin resistance.....	324
6. TBC1D4 p.Arg684Ter – the effect of genetic drift or positive selection.....	325
7. Genetics of glycaemic traits – similarities between the European, Asian, and isolated Greenlandic population.....	325
8. Characterization of human loss-of-function variants in isolated populations.....	326
9. Perspectives.....	327
I.7 When is it MODY? Challenges in Interpretation of Sequence Variants in MODY Genes by <i>Sara Althari & Anna L. Gloyn</i>	330
1. What is maturity-onset diabetes of the young (MODY)?.....	330
2. Who has MODY? Discovery of genetic culprits and estimations of prevalence.....	331
3. Efforts to find the missed and mis-diagnosed MODY cases.....	333
3.1 Why an accurate molecular diagnosis of MODY matters.....	333
3.2 Current MODY detection methods.....	334
3.3 How biomarkers help to find and classify MODY.....	335
4. The challenge: when does a sequence variant cause MODY?.....	336
4.1 Incomplete penetrance: monogenic disease variant, no monogenic disease.....	336
4.2 Assessing variant causality: contextualize with caution.....	338
5. Establishing the functional consequences of variants in known MODY genes.....	338
5.1 Using in vitro assays to uncover the functional impact of mutant alleles.....	338
5.2 A new dawn for molecular characterization of mutant alleles.....	341
6. Conclusions.....	343
Chapter II. Prevention and Treatment	349
II.1 Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics by <i>Aaron Leong & James B. Meigs</i>	351
1. Introduction.....	351
2. Discovery of HbA1c-related genomic loci.....	352
2.1 HbA1c discovery GWAS.....	352
2.2 Glycaemic and nonglycaemic pathways: genetic architecture of HbA1c in relation to that of T2D and related traits.....	353
3. Implications for T2D diagnosis and population screening.....	356
4. Implications for T2D risk stratification and prediction.....	358
5. Conclusions.....	359
II.2 Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy by <i>Harald Staiger, Elke Schaeffeler, Matthias Schwab & Hans-Ulrich Häring</i>	363
1. Genetics of type 2 diabetes.....	363
2. Modern diabetes therapy.....	364
3. Pharmacogenetics and drug targets.....	365
3.1 Gene variants affecting the response to metformin.....	365
3.2 Gene variants affecting the response to DPP4 inhibitors.....	371
3.3 Gene variants affecting the response to SGLT2 inhibitors.....	372
4. Clinical relevance of pharmacogenetic knowledge today.....	372